Kalaris Therapeutics (KLRS) Other Accumulated Expenses (2019 - 2026)

Kalaris Therapeutics' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 2227.83% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (up 2227.83% YoY), while the FY2025 annual figure was $4.3 million, up 551.75% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $5.4 million, up from $4.3 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $5.4 million in Q1 2026, with the low at $35000.0 in Q2 2024.
• The 5-year median for Other Accumulated Expenses is $659000.0 (2024), against an average of $1.3 million.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses tumbled 88.45% in 2024, then surged 7037.14% in 2025.
• Kalaris Therapeutics' Other Accumulated Expenses stood at $828000.0 in 2022, then climbed by 24.76% to $1.0 million in 2023, then slumped by 36.21% to $659000.0 in 2024, then surged by 551.75% to $4.3 million in 2025, then increased by 24.66% to $5.4 million in 2026.
• Business Quant data shows KLRS's Other Accumulated Expenses at $5.4 million in Q1 2026, $4.3 million in Q4 2025, and $3.6 million in Q3 2025.